Literature DB >> 25648332

Calibration weighted estimation of semiparametric transformation models for two-phase sampling.

Youyi Fong1, Peter Gilbert.   

Abstract

Two-phase designs are commonly used to subsample subjects from a cohort in order to study covariates that are too expensive to ascertain for everyone in the cohort. This is particularly true for the study of immune response biomarkers in vaccine immunology, where new, elaborate assays are constantly being developed to improve our understanding of the human immune responses to vaccines and how the immune response may protect humans from virus infection. It has long being recognized that if there exist variables that are correlated with expensive variables and can be measured for every subject in the cohort, they can be leveraged to improve the estimation efficiency for the effects of the expensive variables. In this research article, we developed an improved inverse probability weighted estimation approach for semiparametric transformation models with a two-phase study design. Semiparametric transformation models are a class of models that include the Cox PH and proportional odds models. They provide an attractive way to model the effects of immune response biomarkers as human immune responses generally wane over time. Our approach is based on weights calibration, which has its origin in survey statistics and was used by Breslow et al. to improve inverse probability weighted estimation of the Cox regression model. We develop asymptotic theory for our estimator and examine its performance through simulation studies. We illustrate the proposed method with application to two HIV-1 vaccine efficacy trials.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Cox PH model; linear transformation models; proportional odds model; raking estimator; vaccine efficacy trial

Mesh:

Substances:

Year:  2015        PMID: 25648332      PMCID: PMC4390487          DOI: 10.1002/sim.6439

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Using the whole cohort in the analysis of case-cohort data.

Authors:  Norman E Breslow; Thomas Lumley; Christie M Ballantyne; Lloyd E Chambless; Michal Kulich
Journal:  Am J Epidemiol       Date:  2009-04-08       Impact factor: 4.897

3.  Analysis of survival data by the proportional odds model.

Authors:  S Bennett
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

4.  Improved Horvitz-Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology.

Authors:  Norman E Breslow; Thomas Lumley; Christie M Ballantyne; Lloyd E Chambless; Michal Kulich
Journal:  Stat Biosci       Date:  2009-05-01

5.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

7.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

8.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

9.  Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Authors:  Ann Duerr; Yunda Huang; Susan Buchbinder; Robert W Coombs; Jorge Sanchez; Carlos del Rio; Martin Casapia; Steven Santiago; Peter Gilbert; Lawrence Corey; Michael N Robertson
Journal:  J Infect Dis       Date:  2012-05-04       Impact factor: 5.226

  9 in total
  2 in total

1.  Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Authors:  Holly E Janes; Kristen W Cohen; Nicole Frahm; Stephen C De Rosa; Brittany Sanchez; John Hural; Craig A Magaret; Shelly Karuna; Carter Bentley; Raphael Gottardo; Greg Finak; Douglas Grove; Mingchao Shen; Barney S Graham; Richard A Koup; Mark J Mulligan; Beryl Koblin; Susan P Buchbinder; Michael C Keefer; Elizabeth Adams; Chuka Anude; Lawrence Corey; Magdalena Sobieszczyk; Scott M Hammer; Peter B Gilbert; M Juliana McElrath
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

2.  Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials.

Authors:  Nima S Hejazi; Mark J van der Laan; Holly E Janes; Peter B Gilbert; David C Benkeser
Journal:  Biometrics       Date:  2020-09-28       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.